INBP INTEGRATED BIOPHARMA INC
Pharmaceutical Preparations · OTC · SEC CIK 1016504 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-23.1%
TTM net income YoY-644.0%
TTM EPS YoY-650.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin-0.8%
Operating margin-9.3%
Net margin-8.9%
FCF margin-3.8%
EBITDA margin-8.6%
Returns
ROE-19.5%
ROA-14.8%
ROIC (approx.)-20.4%
Asset turnover1.66x
Leverage & solvency
Liabilities / assets29.2%
Debt / equity0.00x
Current ratio2.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $43.87M | $54.35M |
| Cost of revenue | $43.07M | $48.79M |
| Gross profit | $800,000 | $5.56M |
| SG&A expense | $3.50M | $3.54M |
| Operating income | -$2.71M | $2.02M |
| Interest expense | $12,000 | $46,000 |
| Pretax income | -$2.56M | $2.06M |
| Income tax | $279,000 | $1.25M |
| Net income | -$2.84M | $808,000 |
| EBITDA | -$2.41M | $2.34M |
| EPS (basic) | -0.09 | 0.03 |
| EPS (diluted) | -0.09 | 0.03 |
| Weighted avg. shares (diluted) | 31.06M | 31.17M |
| Balance sheet | ||
| Cash & equivalents | $4.47M | $3.62M |
| Receivables | $3.33M | $5.43M |
| Inventory | $9.14M | $9.36M |
| Current assets | $17.38M | $18.76M |
| PP&E, net | $1.75M | $1.72M |
| Total assets | $25.34M | $24.90M |
| Current liabilities | $5.80M | $4.25M |
| Total liabilities | $7.67M | $4.58M |
| Shareholders' equity | $17.67M | $20.32M |
| Shares outstanding | 31.06M | 31.06M |
| Cash flow statement | ||
| Operating cash flow | $1.24M | $2.06M |
| Capital expenditure | $346,000 | $191,000 |
| Free cash flow | $895,000 | $1.87M |
| Investing cash flow | -$340,000 | -$205,000 |
| Financing cash flow | -$45,000 | $78,000 |
| Depreciation & amortization | $293,000 | $318,000 |
| Stock-based compensation | $192,000 | $185,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.